Clinical Trials Logo
  1. Home
  2. Cystinosis
  3. NCT04125927

Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2) — SCOB2  

Cystinosis Clinical Trial

Official title:
Open-label, Single-arm, Multicenter Study to Assess the Safety of Cystadrops® in Pediatric Cystinosis Patients From 6 Months to Less Than 2 Years Old

Clinical Trial Summary

Cystadrops® is currently indicated in adults and children from 2 years of age diagnosed with cystinosis with corneal crystal accumulation observed. However administration of Cystadrops® in patients below 2 years old could be of value for these patients and prevent the crystal deposit. It is the reason why as part of the Cystadrops® pediatric investigational plan (PIP), RECORDATI Rare Diseases committed to conduct a clinical study to assess Cystadrops® safety and efficacy in the pediatric population from 6 months to less than 2 years old.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04125927
Study type Interventional
Source Recordati Rare Diseases
Contact
Status Completed
Phase Phase 3
Start date September 1, 2020
Completion date December 23, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05545774 - Neuromuscular Characterisation in Late Adolescent and Adult Cystinosis Patients
Completed NCT01432561 - Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™ N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT00071903 - The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study N/A
Recruiting NCT05994534 - PK and PD Study of NPI-001 and Cysteamine Bitartrate Phase 1/Phase 2
Completed NCT00004350 - Evaluation of Fanconi Syndrome and Cystinosis N/A
Completed NCT00004312 - Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT02533076 - The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients Phase 0
Enrolling by invitation NCT05146830 - A Long-Term Follow-Up Study of Participants With Cystinosis Who Previously Received CTNS-RD-04
Completed NCT00872729 - Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis Phase 1/Phase 2
Completed NCT00001736 - New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis Phase 1
Recruiting NCT05959668 - Development of Health-related Quality of Life Instrument for Patients With Cystinosis
Withdrawn NCT02124070 - Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis Phase 1/Phase 2
Completed NCT01614431 - N Acetyl Cysteine for Cystinosis Patients Phase 4
Recruiting NCT05843851 - Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria N/A
Completed NCT01000961 - Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis Phase 3
Active, not recruiting NCT03897361 - Stem Cell Gene Therapy for Cystinosis Phase 1/Phase 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford